Congenital Amegakaryocytic Thrombocytopenia (CAMT)

Clinical Background and Genetics
- Congenital amegakaryocytic thrombocytopenia (CAMT: OMIM# 604498) is a rare autosomal recessive bone marrow failure syndrome characterised by severe thrombocytopenia from birth, absent or decreased numbers of megakaryocytes in the bone marrow and low platelet counts.
- Development of pancytopenia in later childhood is common. CAMT patients often develop complete bone marrow failure and have poor prognosis without definitive treatment with allogeneic stem cell transplant.
- CAMT is caused by autosomal recessive mutations in the MPL gene.
- The UK prevalence is unknown, however it is estimated that 10-15 new diagnoses are made annually.
- CAMT is clinically difficult to distinguish from other disorders with similar presentations including other heritable non-syndromic thrombocytopenia and bone-marrow failure syndromes and from other acquired causes of these presentations.
- The 12 exon MPL gene (1p34) encodes the thrombopoietin (TPO) receptor which is the main regulator of megakaryocyte proliferation and differentiation.
- AR mutations in MPL have also been reported in patients presenting with tri-lineage bone marrow failure (aplastic anaemia) (Walne et al 2012) Haematol 97(4):524).
- Early and definitive diagnosis through MPL gene sequencing enables early intervention improving prognosis.

Referrals
- Diagnostic referrals are accepted from Consultant Haematologists and Clinical Geneticists with the following criteria:
  - Pedigree compatible with autosomal recessive inheritance.
  - Patient with persistent thrombocytopenia or bone marrow failure.
  - Absent or markedly reduced megakaryocytes in marrow or multi-lineage marrow aplasia or hypoplasia.
  - Absence of syndromic features associated with other heritable thrombocytopenias.
- Carrier Testing: Testing of parental samples is offered once the mutations have been identified in the affected patient.
- Cascade testing for familial mutations can be undertaken on close adult relatives and siblings where HLA compatibility is indicated.
- Prenatal diagnosis is available if the pathogenic familial MPL mutations have been identified. Please contact the laboratory to discuss.

Routine mutation analysis of the MPL gene is performed by sanger sequencing.

The MPL gene is also included in a 45 gene panel for inherited bone marrow failure syndromes which uses Next Generation Sequencing (NGS). This panel also includes the genes GATA1, FBXW8, RUNX1 and WAS which are associated with Thrombocytopenia. Please contact the laboratory for further information on this service.

Target reporting Time
- Full Gene Screen: 56 days
- Familial Mutation Testing: 14 days
- Prenatal Diagnosis: 3 days

Quality: This laboratory participates in the following external quality assurance schemes which cover the technique and strategies used for this service: EMQN Sanger DNA sequencing scheme (since the pilot scheme was introduced in 2002) and UKNEQAS Pathogenicity of sequence variants interpretation only scheme (pilot scheme introduced in 2012).

Clinical Advice: Dr Andrew Mumford, Consultant Haematologist and Reader in Haematology, Bristol Royal Infirmary Tel: 0117 342 3152 A.Mumford@bristol.ac.uk

Contact details:
Bristol Genetics Laboratory
Pathology Sciences and Bristol Genetics
Southmead Hospital
Bristol, BS10 5NB
Enquiries: 0117 414 6168
FAX: 0117 414 6464
Email: nbn-tr.geneticsenquiries@nhs.net
Head of Department: Eileen Roberts FRCPath
Consultant Lead for Molecular Genetics: Maggie Williams FRCPath
Service Lead: Laura Yarram-Smith
Email: laura.yarram@nbt.nhs.uk
Sample Required:
Adult: 5mls blood in EDTA
Paediatric: at least 1ml EDTA (preferably >2ml)
Prenatal testing MUST be arranged with the laboratory well in advance.
Samples should be accompanied by a FULLY completed request form (available as download at www.nbt.nhs.uk/ genetics or from the laboratory).
Please include details of test, family history, address and POSTCODE, NHS number, referring clinician and unit/hospital.
Consent and DNA Storage:
All genetic testing requires consent. It is the responsibility of the referring clinician to ensure that appropriate consent has been obtained.
DNA is stored from all patients unless consent for this is specifically denied.
Stored samples may be used for quality assurance purposes and may be used anonymously for the development of new tests for the disorder in question.

Information document No 66 version 5
Active date of this version: 25/08/2016
DETAILS CORRECT AT DATE OF PRINTING ONLY.
Approved by: Laura Yarram-Smith

Exceptional healthcare, personally delivered